Specialty Pharmacy

A relationship between hepatitis C and cancer is reinforced by data from epidemiologic research.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.

Particles are surrounded by a protective coating to release drugs in the presence of a specific tumor enzyme.

Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).

Compound reduces residual levels from infected dormant cells.

Top stories of the week on Specialty Pharmacy Times from July 20 to 24.

The FDA has expanded the indication for Amgen's carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone to treat patients with relapsed multiple myeloma who have received at least 1 prior therapy.

With biosimilars set to enter the US health care market, pharmacists will soon have new factors to consider when selecting and dispensing products.

Colonoscopy can catch tumors in a more treatable stage.

Cholesterol-lowering drug is expected to cost between $7,000 and $12,000 annually.

Technivie with ribavirin is the first drug to demonstrate safety and efficacy in genotype 4 infections without interferon.

Sonidegib treats adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy.

Company alleges insurers are taking advantage of program to shift cost of Sovaldi.

Within 48 hours of taking the drug, many patients saw decreased potassium levels.

Test distinguishes between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

PCSK9 inhibitors could cost up to $23.3 billion nationally if widely prescribed.

Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can best utilize data analytics.

Researchers explore potential of sunscreens with cancer-preventive properties.

New process may lead to quicker and more accurate screening processes for drug development.

New procedure seeks to guide therapeutic decisions.

Drug cost mitigated by savings in health care costs on management of conditions that may result from chronic hepatitis C virus.

Silver is a useful element to prevent bacterial growth.

Study finds less than half of cancer patients have a completed will.

International Academy of Compounding Pharmacists raises several concerns regarding FDA policies.

Many pharmacists are required to work on their feet for long hours, but that can have serious health consequences similar to sitting.

Treating hepatitis C patients who receive health care through Medicaid with Sovaldi could exceed $55 billion.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses methods to improve patient access to specialty medications.

Combination of grazoprevir and elbasvir has been studied in patients with genotype 1 hepatitis C who also have end-stage renal disease and are undergoing regular hemodialysis.